Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for sleep disturbance in uncontrolled persistent asthma
NL-OMON52410Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change in sleep disturbance score in Asthma Sleep Disturbance Questionnaire. Started Feb 2021; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON52410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52410.